These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Phosphodiesterase inhibitors in airways disease. Fan Chung K Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289 [TBL] [Abstract][Full Text] [Related]
4. PDE inhibitors currently in early clinical trials for the treatment of asthma. Matera MG; Page C; Cazzola M Expert Opin Investig Drugs; 2014 Sep; 23(9):1267-75. PubMed ID: 24865624 [TBL] [Abstract][Full Text] [Related]
5. Selective PDE inhibitors as novel treatments for respiratory diseases. Page CP; Spina D Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841 [TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth BJ Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300 [TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Page CP; Spina D Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650 [TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Ochiai K; Takita S; Kojima A; Eiraku T; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y Bioorg Med Chem Lett; 2013 Jan; 23(1):375-81. PubMed ID: 23200255 [TBL] [Abstract][Full Text] [Related]
9. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells. BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275 [TBL] [Abstract][Full Text] [Related]
11. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Schmidt DT; Watson N; Dent G; Rühlmann E; Branscheid D; Magnussen H; Rabe KF Br J Pharmacol; 2000 Dec; 131(8):1607-18. PubMed ID: 11139438 [TBL] [Abstract][Full Text] [Related]
12. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration. Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091 [TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity. Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304 [TBL] [Abstract][Full Text] [Related]
14. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Giembycz MA; Newton R Handb Exp Pharmacol; 2011; (204):415-46. PubMed ID: 21695651 [TBL] [Abstract][Full Text] [Related]
15. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Banner KH; Trevethick MA Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712 [TBL] [Abstract][Full Text] [Related]
16. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Cazzola M; Calzetta L; Rogliani P; Matera MG Expert Opin Investig Drugs; 2019 Oct; 28(10):827-833. PubMed ID: 31474120 [No Abstract] [Full Text] [Related]
17. Phosphodiesterase-4 inhibitor therapy for lung diseases. Beghè B; Rabe KF; Fabbri LM Am J Respir Crit Care Med; 2013 Aug; 188(3):271-8. PubMed ID: 23656508 [TBL] [Abstract][Full Text] [Related]
18. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma. Al-Sajee D; Yin X; Gauvreau GM Expert Opin Pharmacother; 2019 Apr; 20(5):609-620. PubMed ID: 30722707 [TBL] [Abstract][Full Text] [Related]
19. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Cazzola M; Page C; Calzetta L; Matera MG Pharm Pat Anal; 2018 Nov; 7(6):249-257. PubMed ID: 30657422 [TBL] [Abstract][Full Text] [Related]
20. 5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles. Afzal F; Andressen KW; Mørk HK; Aronsen JM; Sjaastad I; Dahl CP; Skomedal T; Levy FO; Osnes JB; Qvigstad E Br J Pharmacol; 2008 Dec; 155(7):1005-14. PubMed ID: 18846035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]